Gainplan LLC acquired a new stake in shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) during the second quarter, Holdings Channel reports. The institutional investor acquired 4,400 shares of the company’s stock, valued at approximately $231,000. Aerie Pharmaceuticals comprises 0.2% of Gainplan LLC’s portfolio, making the stock its 6th largest position.

Other institutional investors have also made changes to their positions in the company. Goldman Sachs Group Inc. increased its position in shares of Aerie Pharmaceuticals by 28.5% in the first quarter. Goldman Sachs Group Inc. now owns 223,053 shares of the company’s stock valued at $10,115,000 after buying an additional 49,473 shares during the last quarter. BlackRock Inc. increased its position in shares of Aerie Pharmaceuticals by 113,376.8% in the first quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock valued at $117,951,000 after buying an additional 2,598,596 shares during the last quarter. Parametric Portfolio Associates LLC increased its position in shares of Aerie Pharmaceuticals by 5.8% in the first quarter. Parametric Portfolio Associates LLC now owns 68,398 shares of the company’s stock valued at $3,102,000 after buying an additional 3,739 shares during the last quarter. Turner Investments LLC acquired a new position in shares of Aerie Pharmaceuticals during the first quarter valued at approximately $227,000. Finally, Vanguard Group Inc. increased its position in shares of Aerie Pharmaceuticals by 7.1% in the first quarter. Vanguard Group Inc. now owns 1,392,525 shares of the company’s stock valued at $63,151,000 after buying an additional 92,463 shares during the last quarter. Institutional investors and hedge funds own 92.98% of the company’s stock.

Shares of Aerie Pharmaceuticals, Inc. (NASDAQ AERI) opened at 50.35 on Friday. The company’s market capitalization is $1.83 billion. Aerie Pharmaceuticals, Inc. has a 52 week low of $18.35 and a 52 week high of $59.50. The firm’s 50-day moving average price is $54.55 and its 200 day moving average price is $48.00.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.84) by $0.02. Equities analysts predict that Aerie Pharmaceuticals, Inc. will post ($2.56) EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/08/12/gainplan-llc-invests-231000-in-aerie-pharmaceuticals-inc-aeri.html.

Several equities analysts have recently commented on AERI shares. HC Wainwright restated a “buy” rating and issued a $69.00 price objective on shares of Aerie Pharmaceuticals in a research report on Wednesday, May 3rd. Needham & Company LLC lifted their target price on Aerie Pharmaceuticals from $58.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, May 25th. Cowen and Company reaffirmed an “outperform” rating and issued a $70.00 target price on shares of Aerie Pharmaceuticals in a report on Tuesday, April 18th. Canaccord Genuity set a $56.00 target price on Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, May 22nd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $70.00 target price on shares of Aerie Pharmaceuticals in a report on Friday, July 28th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Aerie Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $66.08.

In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $55.95, for a total value of $1,119,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 9.36% of the company’s stock.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.